Rhythm Biosciences (ASX:RHY) has commenced commercialisation of its flagship blood-based colorectal cancer test, ColoSTAT, following the update and renewal of its ISO15189:2022 laboratory accreditation.
The test will initially be offered as an alternative for symptomatic individuals where stool-based screening is unsuitable, unavailable, or not preferred, addressing a significant unmet clinical need.
Commercial rollout will begin through Rhythm's Melbourne-based certified laboratory under the ColoSTAT Access Program, which engages selected clinical leaders to offer the test, generate real-world data, and support broader market adoption.
The company plans a variation to scope assessment with the National Association of Testing Authorities in January 2026 to formally establish ColoSTAT as an accredited laboratory service, further bolstering clinician confidence and scalability.